Decheng Capital Global Life Sciences Fund IV, L.P.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
Pre-open
Investors
—
Min Invest
None stated
What this filing shows
·Every sentence is a value as filed on SEC Form D
Decheng Capital Global Life Sciences Fund IV, L.P. is a Cayman Islands entity that filed a Form D with the SEC on December 15, 2020, describing itself as a venture capital fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) and covers pooled investment fund interests. Decheng Capital Global Life Sciences Fund IV, L.P. reported that the first sale had not yet occurred as of the Form D filed December 15, 2020, so no amount sold or investor count is on file. The total offering amount is $650,000,000. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing checks both Section 3(c)(1), which caps the fund at 100 beneficial owners, and Section 3(c)(7), which requires every investor to be a qualified purchaser, generally an individual with at least $5 million in investments. A fund normally relies on one or the other. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is C/O Maples Corporate Services Limited, Ugland House, P.O. Box 309, Grand Cayman, Cayman Islands KY1-1104.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Fund Family
Every vehicle in this manager's series as it appears on EDGAR, newest generation first. Sold-to-date and investor counts are each vehicle's latest Form D.
Fund family
Decheng Capital Global Life Sciences Fund2 vehicles · 2 generations · since 2020 · $452.0M sold across the family
This issuer is in Fund IV
| Vehicle | Role | First filed | Status | Sold | Investors |
|---|---|---|---|---|---|
| Fund V · first filed 2024-06-17 · 1 vehicle · $452.0M sold · 42 investors | |||||
| Decheng Capital Global Life Sciences Fund V, L.P. | 2024-06-17 | raising | $452.0M | 42 | |
| Fund IV · first filed 2020-12-15 · 1 vehicle | |||||
| Decheng Capital Global Life Sciences Fund IV, L.P.this issuer | 2020-12-15 | pre sale | $0 | 0 | |
Grouped from Form D issuer names (generation, sleeve, jurisdiction and legal-form tokens removed); a name-only match, so abbreviated or renamed vehicles can be missed. Sold and investor figures are each vehicle's latest Form D; sleeves that report the same figure share one family-wide total and are counted once. Performance lines are what a public pension plan reports for its own interest in that fund, net, on the plan's cash flows and valuation date; they are not the general partner's figures.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Investor
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 293073 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a venture capital fund
Auditor named on Form ADV: PricewaterhouseCoopers LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data through December 31, 2024, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Decheng Capital Management IV (Cayman), LLC
Promoter · Grand Cayman, E9
General Partner of the Issuer
Xiangmin Cui
Promoter · Grand Cayman, E9
Manager of the General Partner of the Issuer
Fengying Yu
Promoter · Grand Cayman, E9
Manager of the General Partner of the Issuer
Questions About Decheng Capital Global Life Sciences Fund IV, L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Decheng Capital Global Life Sciences Fund IV, L.P.?
Decheng Capital Global Life Sciences Fund IV, L.P. is a Cayman Islands entity that filed a Form D with the SEC on December 15, 2020 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) for an offering of pooled investment fund interests.
Is Decheng Capital Global Life Sciences Fund IV, L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Decheng Capital Global Life Sciences Fund IV, L.P. filed a Form D with the SEC on December 15, 2020 claiming Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Decheng Capital Global Life Sciences Fund IV, L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Decheng Capital Global Life Sciences Fund IV, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Decheng Capital Global Life Sciences Fund IV, L.P. raised?
Decheng Capital Global Life Sciences Fund IV, L.P. reported that the first sale had not yet occurred as of the Form D filed December 15, 2020, so no amount sold or investor count is on file. The total offering amount is $650,000,000.
Who can invest in Decheng Capital Global Life Sciences Fund IV, L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing checks both Section 3(c)(1), which caps the fund at 100 beneficial owners, and Section 3(c)(7), which requires every investor to be a qualified purchaser, generally an individual with at least $5 million in investments. A fund normally relies on one or the other. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Decheng Capital Global Life Sciences Fund IV, L.P.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Decheng Capital Global Life Sciences Fund IV, L.P. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Decheng Capital Global Life Sciences Fund IV, L.P.?
The Form D lists 3 related persons: Decheng Capital Management IV (Cayman), LLC, promoter (General Partner of the Issuer); Xiangmin Cui, promoter (Manager of the General Partner of the Issuer); Fengying Yu, promoter (Manager of the General Partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Decheng Capital Global Life Sciences Fund IV, L.P. located?
The issuer's address on its SEC filings is C/O Maples Corporate Services Limited, Ugland House, P.O. Box 309, Grand Cayman, Cayman Islands KY1-1104. Its phone number of record is 345-949-8066. It is organized under the laws of Cayman Islands.
How long is the Decheng Capital Global Life Sciences Fund IV, L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Decheng Capital Global Life Sciences Fund IV, L.P.?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.